Platelet Response During the Second Cycle of Decitabine Can Predict Response and Survival for Myelodysplastic Syndrome

N/AUnknownNCT02045654

Samsung Medical Center1 enrolled

Overview

To assess the efficacy of decitabine and identify predictors for response to decitabine therapy.

* Histologically confirmed Myelodysplastic syndrome Diagnosed with MDS (de novo or secondary) based on the World Health Organization (WHO) classifications * Survival and response Analysis * Response rate * Overall survival * Leukemia free survival

Study Type

OBSERVATIONAL

Enrollment

Conditions

Myelodysplastic Syndrome

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Histologically confirmed Myelodysplastic syndrome Diagnosed with MDS (de novo or secondary) based on the World Health Organization (WHO) classifications

Locations (1)

Division of Hematology Oncology, Samsung Medical Center

Seoul, South Korea

RECRUITING

Outcomes

Primary Outcomes

Response rate

International Working Group (IWG) response criteria

Time frame: 1 year

Secondary Outcomes

Overall survival

measured from the date of decitabine therapy to the date of death or the last follow-up visit

Time frame: 1 year

Leukemia free survival

the date of decitabine therapy to the date of death or leukemic transformation

Time frame: 1 year

Central Contacts

Jun Ho Jang, Pf

CONTACT

jh21.jang@samsung.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.